Full details, including potential risk factors, are given in the Press Release, which can be consulted by clicking on the link below
Nicox’s Positive End-of-Phase 2 Meeting with the U.S. FDA Sets Stage for NCX 470 Phase 3 Program in Glaucoma

March 5, 2020

View Press Release Corporate presentation Contact us
Previous